This report investigates the year 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
Scope
This 50-page report gives important, expert insight you won’t find in any other source. 25 figures throughout the report illustrate major points and trends in Artificial Intelligence. This report is required reading for :- Investors that want to understand current artificial intelligence trends impacting the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in seeing the extent and impact of artificial Intelligence and how best to pivot towards it.
- Large pharma companies with investment groups or BD teams looking to see which artificial Intelligence led biopharmaceutical companies lead the industry currently and what their focuses are on
- Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
- Insights on how drug development in 2023 may impact future approvals
- Insights on how drug approvals in 2023 may impact future drug development and approval trends
- Sales and regulatory-based insights into 2023 covering various drugs and companies
Table of Contents
1 Executive Summary2 2023 Pipeline Development
2.1 Top pipeline therapy areas
2. 2 Pipeline drugs by highest development stage
2.3 Top drugs by molecule type
2.4 Top drugs by target
3 2023 Approvals
3.1 FDA, EMA, Japan regulatory approvals, 2019-2023
3.2 US Fast Track Designation approvals, 2019-2023
3.3 Rare Pediatric disease designation approvals, 2019-2023
4 2023 Sales
4.1 2022 vs 2023 sales
4.2 2022 vs 2023 company market capitalization
4.3 Changes of clinical trial trends
5 Key Findings
6 Appendix
6.1 Abbreviations
6.2 Methodology
6.3 Related Reports
6.4 About the Authors
6.5 About the Analyst
6.6 Contact the Publisher
